Correlation Between Molecular Partners and Acrivon Therapeutics,
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Molecular Partners and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Acrivon Therapeutics,.
Diversification Opportunities for Molecular Partners and Acrivon Therapeutics,
0.62 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Molecular and Acrivon is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Molecular Partners i.e., Molecular Partners and Acrivon Therapeutics, go up and down completely randomly.
Pair Corralation between Molecular Partners and Acrivon Therapeutics,
Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.52 times more return on investment than Acrivon Therapeutics,. However, Molecular Partners is 1.52 times more volatile than Acrivon Therapeutics, Common. It trades about 0.0 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.22 per unit of risk. If you would invest 567.00 in Molecular Partners AG on August 24, 2024 and sell it today you would lose (25.00) from holding Molecular Partners AG or give up 4.41% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Molecular Partners AG vs. Acrivon Therapeutics, Common
Performance |
| Timeline |
| Molecular Partners |
| Acrivon Therapeutics, |
Molecular Partners and Acrivon Therapeutics, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and Acrivon Therapeutics,
The main advantage of trading using opposite Molecular Partners and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
| Acrivon Therapeutics, vs. Aerovate Therapeutics | Acrivon Therapeutics, vs. Adagene | Acrivon Therapeutics, vs. Rezolute | Acrivon Therapeutics, vs. AN2 Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Complementary Tools
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |